Atlas Trials

Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

Clinical trial NCT00286780 · COMPLETED

Trial details

NCT number
NCT00286780
Sponsor
Ascenta Therapeutics
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia
Start date
2006-01-01
Primary completion
2007-11-01
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.